75. クッシング病 Cushing disease Clinical trials / Disease details

臨床試験数 : 203 / 薬物数 : 191 - (DrugBank : 51) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 128

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-004019-29-IT (EUCTR)	15/07/2021	07/10/2020	Italian study to evaluate the efficacy of retinoic acid and cabergoline therapy in combination in Cushing's disease.	Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: a prospective and randomized study. - CRACCA	Cushing's disease in patients in whom pituitary surgery has not been curative or in situations where it is contraindicated or refused by patient. MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Dostinex Product Name: Cabergolina Product Code: [G02CB03] INN or Proposed INN: CABERGOLINA Other descriptive name: NON COMMERCIAL Trade Name: VESANOID Product Name: Tretinoina Product Code: [L01XX14] INN or Proposed INN: TRETINOINA Other descriptive name: NON COMMERCIAL	Dipartimento di Medicina-DIMED, università di Padova	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	Italy
2	EUCTR2008-006379-65-IT (EUCTR)	27/10/2008	12/11/2008	Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease - Retinoic acid in Cushing`s disease	Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease - Retinoic acid in Cushing`s disease	sperimentation only in patients	INN or Proposed INN: Tretinoin	ISTITUTO AUXOLOGICO ITALIANO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy